Tianda Pharmaceuticals Ltd 2020 SR
The report outlines Tianda Pharmaceuticals Limited's ESG performance for the fiscal year 2019-2020, emphasizing its commitment to Traditional Chinese Medicine and innovative healthcare. Key highlights include the development of 'Anti-Epidemic Formula 1' and the donation of 50,000 masks to Italy during the COVID-19 pandemic. The company implemented rigorous wastewater and solid waste treatment systems, ensuring compliance with national standards. Additionally, the report details a materiality assessment identifying 16 key sustainability issues and highlights community investment initiatives, such as providing internship positions and supporting local cancer research.
Company: Tianda Pharmaceuticals Ltd
Sector: Health Care
Country: Hong Kong
Year: 2020
Type: SR
Pages: 23
Tianda Pharmaceuticals Ltd
ESG Report
The report outlines Tianda Pharmaceuticals Limited's ESG performance for the fiscal year 2019-2020, emphasizing its commitment to Traditional Chinese Medicine and innovative healthcare. Key highlights include the development of 'Anti-Epidemic Formula 1' and the donation of 50,000 masks to Italy during the COVID-19 pandemic. The company implemented rigorous wastewater and solid waste treatment systems, ensuring compliance with national standards. Additionally, the report details a materiality assessment identifying 16 key sustainability issues and highlights community investment initiatives, such as providing internship positions and supporting local cancer research.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2020
Published
Oct 23, 2020
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Energy Consumption
Water Consumption
Total Waste